Report : Europe Hemodialysis and Peritoneal Dialysis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Hemodialysis and Peritoneal Dialysis), Product (Devices, Consumables, and Services), and End User (Hospital-Based and Home-Based)         

At 6.3% CAGR, the Europe hemodialysis and peritoneal dialysis market is speculated to be worth US$ 36,242.91 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe hemodialysis and peritoneal dialysis market was valued at US$ 25,140.48 million in 2022 and is expected to reach US$ 45,277.56 million by 2028, registering an annual growth rate of 6.3% from 2022 to 2028. Rising prevalence of kidney diseases and increasing cases of diabetes are the critical factors attributed to the market expansion.

Chronic kidney disease (CKD) and acute kidney injury (AKI) are conditions in which the kidneys are damaged and cannot filter blood properly. Because of this, excess fluid and waste from blood remain in the body, which may cause other health problems such as heart disease and stroke. CKD usually worsens over time, even though treatment has shown slow progression. If CKD is left untreated, it can progress to kidney failure and early cardiovascular disease. In CKD, when the kidneys stop working, dialysis or kidney transplant is needed for survival. When treated with dialysis or kidney transplant, this kidney failure is called end-stage renal disease (ESRD). The increasing prevalence of ESRD is also one of the major factors driving the market. Thus, the increasing prevalence of chronic kidney disease, acute kidney injury, and end-stage renal disease, which leads to the condition of dialysis, is driving the hemodialysis and peritoneal dialysis market.    

On the contrary, various risks and complications associated with dialysis hurdles the growth of Europe hemodialysis and peritoneal dialysis market.

Based on type, the Europe hemodialysis and peritoneal dialysis market is bifurcated into hemodialysis and peritoneal dialysis. The former held 87.5% market share in 2022, amassing US$ 21,991.01 million. It is projected to garner US$ 32,038.92 million by 2028 to expand at 6.5% CAGR during 2022–2028.      

Based on product, the Europe hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. With 64.2% share of the domain, the services segment dominated the market in 2022. It accrued US$ 16,142.90 million in 2022 and is estimated to generate US$ 23,285.96 million by 2028 to grow at a CAGR of 6.3% over the forecast period.     

Based on end user, the Europe hemodialysis and peritoneal dialysis market is segmented into hospital-based and home-based. The hospital-based segment held a larger share in 2022 with a market share of 88.4%. Further it accrued US$ 22,263.20 million in 2022 and is expected to reach at US$ 31,689.47 million at a decent CAGR of 6.1% during the forecast period.

Our regional analysis states that Germany captured 29.5% market share in 2022. It was assessed at US$ 7,403.87 million in 2022 and is likely to hit US$ 10,434.33 million by 2028, exhibiting a CAGR of 5.9% during the forecast period.   

Key players dominating the Europe hemodialysis and peritoneal dialysis market are Asahi Kasei Medical Co., Ltd.; B. Braun Melsungen AG; Baxter International Inc.; DaVita Inc.; Dialife SA; Diaverum; Fresenius Medical Care AG & Co KGaA; and Nipro Medical Corporation, among others.

The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance:

  • DaVita Inc. announced the expansion of its collaboration with Fresenius Medical Care's Europen FMS division to provide NxStage home hemodialysis machines and related technologies to patients in the United States. In particular, the agreement supports companies' efforts to allow more people with renal failure to choose home dialysis as an option.
  • B. Braun Melsungen AG acquires a specialist in the preparation of dialysis concentrates, Intermedt Medizin & Technik GmbH. The acquisition has helped B. Braun Melsungen AG to complete the extensive product portfolio of its B. Braun Avitum division as a systems provider for extracorporeal blood treatment (dialysis).  

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id:

Download Free PDF Brochure